Established a reliable biomarker in terms of postoperative adjuvant chemotherapy for pancreatic ductal adenocarcinoma

被引：0
|
作者：
Yamada, Daisaku [1 ]
Takeda, Yu [1 ]
Kobayashi, Shogo [1 ]
Sasaki, Kazuki [1 ]
Iwagami, Yoshifumi [1 ]
Tomimaru, Yoshito [1 ]
Noda, Takehiro [1 ]
Takahashi, Hidenori [1 ]
Doki, Yuichiro [1 ]
Eguchi, Hidetoshi [1 ]
机构：
[1] Osaka Univ, Grad Sch Med, Dept Surg Gastroenterol, Osaka, Japan
来源：
CANCER SCIENCE | 2024年 / 115卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-3309
引用
收藏
页码：2138 / 2138
页数：1
相关论文
共 50 条
  • [21] Efficacy of Adjuvant Chemotherapy According to the Pathological Response to Neoadjuvant Chemotherapy Among Patients With Pancreatic Ductal Adenocarcinoma
    Mori, Shozo
    Aoki, Taku
    Sakuraoka, Yuhki
    Shimizu, Takayuki
    Yamaguchi, Takamune
    Park, Kyung-Hwa
    Matsumoto, Takatsugu
    Shiraki, Takayuki
    Iso, Yukihiro
    Kubota, Keiichi
    ANTICANCER RESEARCH, 2021, 41 (03) : 1629 - 1639
  • [22] The investigation of the survival time after recurrence in patients with pancreatic ductal adenocarcinoma for individualization of adjuvant chemotherapy
    Daisaku Yamada
    Hidetoshi Eguchi
    Yoshifumi Iwagami
    Tadafumi Asaoka
    Takehiro Noda
    Koichi Kawamoto
    Kunihito Gotoh
    Shogo Kobayashi
    Masaki Mori
    Yuichiro Doki
    Surgery Today, 2018, 48 : 952 - 962
  • [23] Adjuvant Chemotherapy for Stage I Pancreatic Ductal Adenocarcinoma-Is It Based on Evidence or Clinical Wisdom?
    Gervaso, Lorenzo
    Lordick, Florian
    Fazio, Nicola
    JAMA ONCOLOGY, 2021, 7 (12) : 1759 - 1760
  • [24] Adjuvant Chemotherapy and Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma: A Systematic Review and Clinical Practice Guideline
    Biagi, James J. J.
    Cosby, Roxanne
    Bahl, Mala
    Elfiki, Tarek
    Goodwin, Rachel
    Hallet, Julie
    Hirmiz, Khalid
    Mahmud, Aamer
    CURRENT ONCOLOGY, 2023, 30 (07) : 6575 - 6586
  • [25] Adjuvant chemotherapy after surgery for pancreatic ductal adenocarcinoma: retrospective real-life data
    Sophia Chikhladze
    Ann-Kathrin Lederer
    Lampros Kousoulas
    Marilena Reinmuth
    Olivia Sick
    Stefan Fichtner-Feigl
    Uwe A. Wittel
    World Journal of Surgical Oncology, 17
  • [26] The investigation of the survival time after recurrence in patients with pancreatic ductal adenocarcinoma for individualization of adjuvant chemotherapy
    Yamada, Daisaku
    Eguchi, Hidetoshi
    Iwagami, Yoshifumi
    Asaoka, Tadafumi
    Noda, Takehiro
    Kawamoto, Koichi
    Gotoh, Kunihito
    Kobayashi, Shogo
    Mori, Masaki
    Doki, Yuichiro
    SURGERY TODAY, 2018, 48 (10) : 952 - 962
  • [27] An EMT-Related Gene Signature for Predicting Response to Adjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma
    Feng, Zengyu
    Li, Kexian
    Lou, Jianyao
    Wu, Yulian
    Peng, Chenghong
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
  • [28] Adjuvant chemotherapy and chemoradiation therapy after R0 resection for pancreatic ductal adenocarcinoma
    Ryu, J.
    Lee, S.
    Kim, Y.
    Yang, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S213 - S213
  • [29] Adjuvant Treatment of Surgically Resectable Pancreatic Ductal Adenocarcinoma
    Tesfaye, Anteneh A.
    Philip, Philip A.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (01) : 54 - 63
  • [30] Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma
    Riazy, Maziar
    Kalloger, Steve E.
    Sheffield, Brandon S.
    Peixoto, Renata D.
    Li-Chang, Hector H.
    Scudamore, Charles H.
    Renouf, Daniel J.
    Schaeffer, David F.
    MODERN PATHOLOGY, 2015, 28 (10) : 1383 - 1389
12345